JP2020120689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020120689A5 JP2020120689A5 JP2020085079A JP2020085079A JP2020120689A5 JP 2020120689 A5 JP2020120689 A5 JP 2020120689A5 JP 2020085079 A JP2020085079 A JP 2020085079A JP 2020085079 A JP2020085079 A JP 2020085079A JP 2020120689 A5 JP2020120689 A5 JP 2020120689A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- binding fragment
- set forth
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 27
- 239000000427 antigen Substances 0.000 claims 24
- 102000036639 antigens Human genes 0.000 claims 24
- 108091007433 antigens Proteins 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 9
- 241000725303 Human immunodeficiency virus Species 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 3
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 3
- JKGGPMOUIAAJAA-YEPSODPASA-N Thr-Gly-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O JKGGPMOUIAAJAA-YEPSODPASA-N 0.000 claims 2
- 241000024188 Andala Species 0.000 claims 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021137876A JP7126594B2 (ja) | 2015-12-15 | 2021-08-26 | ヒト免疫不全ウイルス中和抗体 |
| JP2022129584A JP2022163192A (ja) | 2015-12-15 | 2022-08-16 | ヒト免疫不全ウイルス中和抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267652P | 2015-12-15 | 2015-12-15 | |
| US62/267,652 | 2015-12-15 | ||
| JP2018530831A JP6732915B2 (ja) | 2015-12-15 | 2016-12-14 | ヒト免疫不全ウイルス中和抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530831A Division JP6732915B2 (ja) | 2015-12-15 | 2016-12-14 | ヒト免疫不全ウイルス中和抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021137876A Division JP7126594B2 (ja) | 2015-12-15 | 2021-08-26 | ヒト免疫不全ウイルス中和抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020120689A JP2020120689A (ja) | 2020-08-13 |
| JP2020120689A5 true JP2020120689A5 (https=) | 2020-11-12 |
| JP6936361B2 JP6936361B2 (ja) | 2021-09-15 |
Family
ID=58737847
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530831A Active JP6732915B2 (ja) | 2015-12-15 | 2016-12-14 | ヒト免疫不全ウイルス中和抗体 |
| JP2020085079A Active JP6936361B2 (ja) | 2015-12-15 | 2020-05-14 | ヒト免疫不全ウイルス中和抗体 |
| JP2021137876A Active JP7126594B2 (ja) | 2015-12-15 | 2021-08-26 | ヒト免疫不全ウイルス中和抗体 |
| JP2022129584A Withdrawn JP2022163192A (ja) | 2015-12-15 | 2022-08-16 | ヒト免疫不全ウイルス中和抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530831A Active JP6732915B2 (ja) | 2015-12-15 | 2016-12-14 | ヒト免疫不全ウイルス中和抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021137876A Active JP7126594B2 (ja) | 2015-12-15 | 2021-08-26 | ヒト免疫不全ウイルス中和抗体 |
| JP2022129584A Withdrawn JP2022163192A (ja) | 2015-12-15 | 2022-08-16 | ヒト免疫不全ウイルス中和抗体 |
Country Status (37)
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| RS62437B1 (sr) | 2015-10-25 | 2021-11-30 | Sanofi Sa | Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije |
| JP6732915B2 (ja) | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ， インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
| LT3443006T (lt) | 2016-04-13 | 2023-10-25 | Sanofi | Trispecifiniai ir (arba) trivalenčiai rišantieji baltymai |
| CA3020633A1 (en) | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| AR112257A1 (es) | 2017-06-21 | 2019-10-09 | Gilead Sciences Inc | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| CN117924477A (zh) * | 2017-12-19 | 2024-04-26 | 洛克菲勒大学 | 具有改进的效应子功能的人IgG Fc结构域变体 |
| RU2020130795A (ru) * | 2018-02-21 | 2022-03-21 | Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз | Нейтрализующие антитела к env вич-1 и их применение |
| EP3797118A4 (en) * | 2018-05-22 | 2022-06-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| MX2020013621A (es) | 2018-06-19 | 2021-03-25 | Nantcell Inc | Composiciones y metodos de tratamiento de vih. |
| DK4257600T3 (da) | 2018-07-03 | 2025-05-26 | Gilead Sciences Inc | Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem |
| WO2020056383A1 (en) * | 2018-09-13 | 2020-03-19 | Children's National Medical Center | Cells comprising antibodies against human immunodeficiency virus and methods of preparing and using the same |
| WO2020086782A1 (en) * | 2018-10-24 | 2020-04-30 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
| US12459989B2 (en) | 2018-11-21 | 2025-11-04 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (HIV) |
| FI3898668T3 (fi) * | 2018-12-19 | 2023-11-28 | Humabs Biomed Sa | B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä |
| RS67553B1 (sr) | 2018-12-20 | 2026-01-30 | Humabs Biomed Sa | Kombinovana hbv terapija |
| EP3908664A4 (en) | 2019-01-07 | 2023-01-25 | Thomas Jefferson University | MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| TW202231277A (zh) * | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| JP7700093B2 (ja) * | 2019-07-08 | 2025-06-30 | カルフォルニア インスティテュート オブ テクノロジー | 多反応性が低下した抗ｈｉｖワクチン抗体 |
| KR20240137107A (ko) | 2019-07-16 | 2024-09-19 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| EP4041757A4 (en) * | 2019-09-26 | 2024-04-17 | Regents of the University of Minnesota | VIRAL ANTIGEN BINDING NK ENGAGERS COMPOUNDS AND METHODS OF USE |
| JP7502861B2 (ja) * | 2019-12-27 | 2024-06-19 | 旭化成株式会社 | 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2021207635A1 (en) * | 2020-04-09 | 2021-10-14 | The George Washington University | Prussian blue nanoparticles functionalization with latency reversing agents and broadly neutralizing antibodies, and applications thereof |
| CN113899903B (zh) * | 2020-07-06 | 2025-08-29 | 上海市免疫学研究所 | 结直肠癌生物标志物及其在诊断、预防、治疗及预后中的应用 |
| JP7518286B2 (ja) * | 2020-08-25 | 2024-07-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| PL4244396T3 (pl) | 2020-11-11 | 2025-12-22 | Gilead Sciences, Inc. | Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120 |
| US20230000973A1 (en) * | 2021-06-25 | 2023-01-05 | Janssen Vaccines & Prevention B.V. | Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| CR20240223A (es) | 2021-12-03 | 2024-07-08 | Gilead Sciences Inc | Compuestos terapéuticos para la infección por el virus del vih |
| US12404262B2 (en) | 2021-12-03 | 2025-09-02 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TWI867601B (zh) | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| US20240009135A1 (en) * | 2022-07-08 | 2024-01-11 | Merck Sharp & Dohme Llc | Densified co-precipitated materials isolated by thin film evaporation |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| AU2023330037A1 (en) | 2022-08-26 | 2025-03-06 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| US20240390349A1 (en) | 2023-04-19 | 2024-11-28 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121219281A (zh) | 2023-05-31 | 2025-12-26 | 吉利德科学公司 | 用于治疗hiv的化合物的固体形式 |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025049708A1 (en) * | 2023-08-31 | 2025-03-06 | International Aids Vaccine Initiative | Human neutralizing antibodies against hiv env |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250122219A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2026076265A1 (en) | 2024-10-03 | 2026-04-09 | Gilead Sciences, Inc. | Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors |
| CN121203004B (zh) * | 2025-09-25 | 2026-04-10 | 上海原科实业发展有限公司 | 一种游离轻链、质控品及其用途 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5913521B2 (ja) | 1975-06-19 | 1984-03-30 | メイトウサンギヨウ カブシキガイシヤ | 磁性酸化鉄・デキストラン複合体の製造法 |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4454106A (en) | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
| PT81498B (pt) | 1984-11-23 | 1987-12-30 | Schering Ag | Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US7041293B1 (en) | 1990-04-03 | 2006-05-09 | Genentech, Inc. | HIV env antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
| DK2270045T3 (en) | 2004-02-06 | 2015-04-07 | Univ Massachusetts | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF |
| AU2005330489B2 (en) | 2004-07-27 | 2011-08-25 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti HIV agents |
| US20070292390A1 (en) | 2004-10-29 | 2007-12-20 | Dimitrov Dimiter S | Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2611998A1 (en) | 2005-06-13 | 2006-12-21 | Cargill, Incorporated | Objective methods of estimating age of animals and carcasses |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| EP1803814A1 (en) | 2005-12-27 | 2007-07-04 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Method of improving the antibody selection capacity in phage-display library |
| US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
| JP4783325B2 (ja) | 2007-04-09 | 2011-09-28 | 株式会社神戸製鋼所 | 高温排ガスの処理方法 |
| CA2691444C (en) | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| EA019259B1 (ru) | 2007-11-16 | 2014-02-28 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| WO2010014913A1 (en) | 2008-08-01 | 2010-02-04 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| CN102272158B (zh) | 2008-11-12 | 2014-05-07 | 乔治·K·刘易斯 | 源自记忆b细胞的人单克隆抗体的快速表达克隆 |
| RS53347B (sr) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| US20100215691A1 (en) | 2009-02-20 | 2010-08-26 | Parks Christopher L | Recombinant viral vectors |
| SI3260136T1 (sl) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa |
| EP2246364A1 (en) | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| CN105669553A (zh) | 2009-08-18 | 2016-06-15 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
| RU2016108987A (ru) | 2009-08-18 | 2018-11-26 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора |
| JP5694345B2 (ja) | 2009-10-22 | 2015-04-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体の調節因子 |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| MX2012015097A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Derivados de acido naft-2-ilacetico para tratar sida. |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| CN102374226A (zh) | 2010-08-06 | 2012-03-14 | 深圳富泰宏精密工业有限公司 | 套筒、铰链结构及应用该铰链结构的便携式电子装置 |
| PT3556396T (pt) | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Anticorpos neutralizantes do vírus da imunodeficiência humana (vih) |
| JP5871003B2 (ja) | 2010-09-28 | 2016-03-01 | 富士通株式会社 | 共存ワーキングモードをアクティブにする方法並びに基地局、ユーザ装置及びシステム |
| CN103237549A (zh) | 2010-10-01 | 2013-08-07 | 帆德制药股份有限公司 | 过敏性疾病的治疗方法 |
| EP3195868A3 (en) | 2010-10-01 | 2017-08-02 | VentiRx Pharmaceuticals, Inc. | Therapeutic use of a tlr agonist and combination therapy |
| KR101416437B1 (ko) | 2010-11-03 | 2014-07-10 | 한국전자통신연구원 | 파장 가변 외부 공진 레이저 발생 장치 |
| SG10201510402WA (en) | 2010-11-18 | 2016-01-28 | Univ Yale | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
| DK2663555T3 (en) | 2011-01-12 | 2017-03-27 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
| EP3208263A1 (en) | 2011-01-12 | 2017-08-23 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| WO2012106578A1 (en) * | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| PT3590928T (pt) | 2011-04-08 | 2021-08-19 | Janssen Sciences Ireland Unlimited Co | Derivados de pirimidina para o tratamento de infeções virais |
| UA111841C2 (uk) | 2011-04-21 | 2016-06-24 | Гіліад Сайєнсіз, Інк. | Сполуки бензотіазолу та їх фармацевтичне застосування |
| AU2012258220B2 (en) | 2011-05-18 | 2017-01-19 | Janssen Sciences Ireland Uc | Quinazoline derivatives for the treatment of viral infections and further diseases |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| US9399645B2 (en) | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
| BR112014015197A8 (pt) | 2011-12-21 | 2017-06-13 | Novira Therapeutics Inc | agentes antivirais de hepatite b |
| SG11201404743TA (en) | 2012-02-08 | 2014-09-26 | Janssen R & D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
| UY34750A (es) | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
| US11149069B2 (en) | 2012-08-03 | 2021-10-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers |
| MX369417B (es) | 2012-08-10 | 2019-11-07 | Janssen Sciences Ireland Uc | Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades. |
| DK2906563T3 (en) | 2012-10-10 | 2018-06-06 | Janssen Sciences Ireland Uc | PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES |
| EA035431B1 (ru) | 2012-11-16 | 2020-06-15 | Янссен Сайенсиз Айрлэнд Юси | Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| PE20151063A1 (es) | 2012-12-27 | 2015-08-03 | Japan Tobacco Inc | DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH |
| US10066238B2 (en) * | 2013-02-11 | 2018-09-04 | University Of Louisville Research Foundation, Inc. | Methods for producing antibodies |
| SG11201506639XA (en) | 2013-02-21 | 2015-09-29 | Janssen Sciences Ireland Uc | 2-aminopyrimidine derivatives for the treatment of viral infections |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| CA2932405A1 (en) | 2013-12-02 | 2015-06-11 | Aaron Diamond Aids Research Center | Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture |
| JP6522732B2 (ja) * | 2014-07-11 | 2019-05-29 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを治療するためのトール様受容体の調節因子 |
| US9670205B2 (en) | 2015-03-04 | 2017-06-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| JP6732915B2 (ja) | 2015-12-15 | 2020-07-29 | ギリアード サイエンシーズ， インコーポレイテッド | ヒト免疫不全ウイルス中和抗体 |
-
2016
- 2016-12-14 JP JP2018530831A patent/JP6732915B2/ja active Active
- 2016-12-14 BR BR112018012164-9A patent/BR112018012164A2/en not_active IP Right Cessation
- 2016-12-14 TW TW110130315A patent/TWI814056B/zh active
- 2016-12-14 WO PCT/US2016/066658 patent/WO2017106346A2/en not_active Ceased
- 2016-12-14 EA EA201891186A patent/EA201891186A1/ru unknown
- 2016-12-14 US US15/379,157 patent/US10239935B2/en active Active
- 2016-12-14 UA UAA201806361A patent/UA125819C2/uk unknown
- 2016-12-14 AU AU2016370591A patent/AU2016370591C1/en active Active
- 2016-12-14 CA CA3008442A patent/CA3008442C/en active Active
- 2016-12-14 CN CN202210281565.6A patent/CN114848812B/zh active Active
- 2016-12-14 PE PE2018001115A patent/PE20181451A1/es unknown
- 2016-12-14 NZ NZ743713A patent/NZ743713A/en not_active IP Right Cessation
- 2016-12-14 SG SG10202108793TA patent/SG10202108793TA/en unknown
- 2016-12-14 LT LTEPPCT/US2016/066658T patent/LT3390441T/lt unknown
- 2016-12-14 EP EP16867376.2A patent/EP3390441B1/en active Active
- 2016-12-14 CN CN201680079823.5A patent/CN109311967B/zh active Active
- 2016-12-14 HU HUE16867376A patent/HUE056243T2/hu unknown
- 2016-12-14 ES ES16867376T patent/ES2897756T3/es active Active
- 2016-12-14 DK DK16867376.2T patent/DK3390441T3/da active
- 2016-12-14 TW TW105141486A patent/TWI735491B/zh active
- 2016-12-14 MY MYPI2021003644A patent/MY196200A/en unknown
- 2016-12-14 SI SI201631372T patent/SI3390441T1/sl unknown
- 2016-12-14 CR CR20180321A patent/CR20180321A/es unknown
- 2016-12-14 KR KR1020187019806A patent/KR102165120B1/ko active Active
- 2016-12-14 CU CUP2018000062A patent/CU20180062A7/es unknown
- 2016-12-14 EP EP21192543.3A patent/EP3992206A1/en active Pending
- 2016-12-14 AR ARP160103833A patent/AR106991A1/es not_active Application Discontinuation
- 2016-12-14 MY MYPI2018702243A patent/MY186414A/en unknown
- 2016-12-14 MA MA044077A patent/MA44077A/fr unknown
- 2016-12-14 MX MX2018007288A patent/MX2018007288A/es unknown
- 2016-12-14 PL PL16867376T patent/PL3390441T3/pl unknown
- 2016-12-14 EA EA202091898A patent/EA202091898A1/ru unknown
- 2016-12-14 SG SG11201804787UA patent/SG11201804787UA/en unknown
-
2018
- 2018-06-05 IL IL259832A patent/IL259832B/en unknown
- 2018-06-07 ZA ZA2018/03783A patent/ZA201803783B/en unknown
- 2018-06-11 SA SA518391778A patent/SA518391778B1/ar unknown
- 2018-06-13 EC ECIEPI201845028A patent/ECSP18045028A/es unknown
- 2018-06-13 CL CL2018001587A patent/CL2018001587A1/es unknown
- 2018-06-13 SV SV2018005710A patent/SV2018005710A/es unknown
- 2018-06-13 CO CONC2018/0006050A patent/CO2018006050A2/es unknown
- 2018-06-13 DO DO2018000146A patent/DOP2018000146A/es unknown
- 2018-06-14 MX MX2022013524A patent/MX2022013524A/es unknown
- 2018-06-14 PH PH12018501281A patent/PH12018501281A1/en unknown
-
2019
- 2019-02-12 US US16/273,753 patent/US10882898B2/en active Active
- 2019-12-05 AU AU2019275625A patent/AU2019275625B2/en active Active
-
2020
- 2020-05-14 JP JP2020085079A patent/JP6936361B2/ja active Active
- 2020-12-03 US US17/110,876 patent/US11655285B2/en active Active
-
2021
- 2021-01-29 DO DO2021000022A patent/DOP2021000022A/es unknown
- 2021-08-26 JP JP2021137876A patent/JP7126594B2/ja active Active
- 2021-11-04 AU AU2021261910A patent/AU2021261910B2/en active Active
- 2021-11-10 CY CY20211100980T patent/CY1124756T1/el unknown
-
2022
- 2022-08-16 JP JP2022129584A patent/JP2022163192A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020120689A5 (https=) | ||
| US11779651B2 (en) | Bivalent, bispecific binding proteins for prevention or treatment of HIV infection | |
| JP7153696B2 (ja) | ヒト化抗Ｃ１ｓ抗体及びその使用方法 | |
| ES2199941T3 (es) | Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j. | |
| EP2571898B1 (en) | High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins | |
| CN106102837B (zh) | 双特异性hiv-1-中和抗体 | |
| TW201821437A (zh) | 抗Ｃ１ｓ抗體及其使用方法 | |
| JPWO1994020632A1 (ja) | 抗ｈｉｖモノクローナル抗体 | |
| JP2023505492A5 (https=) | ||
| JP2021533204A5 (https=) | ||
| JP2017524675A5 (https=) | ||
| JP2021506945A (ja) | 二重特異性ｈｉｖ−１中和抗体 | |
| JP2024532453A5 (https=) | ||
| AU2003299085B2 (en) | Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome | |
| US20250296988A1 (en) | Combination therapy | |
| JPH11501283A (ja) | Ｉ型インターフェロンに対する中和活性を有する、インターフェロンレセプターに対するモノクローナル抗体を含んでなる医薬組成物 | |
| JP2024532426A5 (https=) | ||
| US20260028397A1 (en) | Methods of treating ankylosing spondylitis | |
| CN120112558A (zh) | 治疗慢性病毒感染的含cd8抗原结合分子的融合物 | |
| CN114127108A (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| JPWO2023190496A5 (https=) | ||
| WO2024123897A1 (en) | Broadly neutralizing and potent antibodies against hiv | |
| WO2002026259A1 (en) | A pharmaceutical composition for treating acids and its preparation | |
| HK40052791A (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| EA040589B1 (ru) | Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv |